Local ablative therapy for Minimal Residual Disease

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, NJ
Minimal Residual Disease+8 More
Local ablative therapy - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.

Eligible Conditions

  • Minimal Residual Disease
  • Malignant Neoplasms
  • Stage IV, NSCLC
  • Non-small Cell Lung Cancer
  • Nsclc

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 3 months +/- 2 weeks after enrollment

Month 3
Progression Free Survival/PFS
6 months
Measure the reduction in mean variant allele frequency/VAF by 6 months after Local Ablative Therapy/LAT

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

Part II - standard of care
1 of 3
Part I
1 of 3
Part II - ablation to all sites of disease (experimental arm)
1 of 3
Active Control
Experimental Treatment

117 Total Participants · 3 Treatment Groups

Primary Treatment: Local ablative therapy · No Placebo Group · Phase 2

Part IExperimental Group · 2 Interventions: Local ablative therapy, Blood collection to assess for ctDNA · Intervention Types: Procedure, Other
Part II - ablation to all sites of disease (experimental arm)Experimental Group · 2 Interventions: Local ablative therapy, Blood collection to assess for ctDNA · Intervention Types: Procedure, Other
Part II - standard of care
Other
ActiveComparator Group · 1 Intervention: Blood collection to assess for ctDNA · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months +/- 2 weeks after enrollment
Closest Location: Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
Photo of new jersey 1Photo of new jersey 2Photo of new jersey 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Minimal Residual Disease
0 CompletedClinical Trials

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,806 Previous Clinical Trials
589,211 Total Patients Enrolled
1 Trials studying Minimal Residual Disease
Daniel Gomez, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
90 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have detectable ctDNA in blood.
You are a participant in the study.
You have received definitive treatment for Stage IV NSCLC

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.